Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel

Results for "

TREK-1 channel inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Chloride Channel (1) Potassium Channel (14) Sodium Channel (7) Isotope-Labeled Compounds (2)
By Research Areas:	Cancer (5) Cardiovascular Disease (7) Neurological Disease (15)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: Chloride Channel Calcium Channel HCN Channel CRAC Channel TRP Channel Sodium Channel Potassium Channel Piezo Channel

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134559

TKIM	Potassium Channel	Neurological Disease
TKIM is a **TREK-1 channel** inhibitor with an IC₅₀ of 2.96 μM. TKIM binds to the pocket of the intermediate (IM) state of TREK-1 .

HY-149538

TWIK-1/TREK-1-IN-3	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects .

HY-137563

A2793	Potassium Channel	Neurological Disease
A2793 is an efficient dual *TWIK-related acid-sensitive K ⁺ channel* (TASK)-1/TRESK** inhibitor, with an IC₅₀ of 6.8 μM for mTRESK. A2764 is more selective for TRESK, and it only moderately influences TREK-1 and TALK-1 .

HY-B0563B

Ropivacaine hydrochloride 5 Publications Verification	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine hydrochloride is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain management in vivo .

HY-B0563

Ropivacaine 5 Publications Verification	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .

HY-B0563A

Ropivacaine hydrochloride monohydrate 5 Publications Verification	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine hydrochloride monohydrate is a potent?sodium channel?blocker and blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain?management in vivo .

HY-B0563S1

Ropivacaine-d7	Isotope-Labeled Compounds Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease
Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].

HY-149536

TWIK-1/TREK-1-IN-1	Potassium Channel	Neurological Disease
TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC₅₀s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects .

HY-116704

11-Deoxyprostaglandin F2α	Potassium Channel	Neurological Disease
11-Deoxyprostaglandin F2α is an activator for *TREK-2* channels with EC₅₀ of 0.294 μM. 11-Deoxyprostaglandin F2α inhibits the K2P channel *TREK-1* .

HY-B0563R

Ropivacaine (Standard)	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine (Standard) is the analytical standard of Ropivacaine. This product is intended for research and analytical applications. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane . Ropivacaine is used for the research of neuropathic pain management .

HY-135809

A2764 dihydrochloride	Potassium Channel	Neurological Disease
A2764 dihydrochloride is a highly selective inhibitor of TRESK (TWIK-related spinal cord K ⁺ channel, K2P18.1), which has moderate inhibitory effects on TREK-1 and TALK-1. A2764 dihydrochloride is more sensitive to the activated mTRESK channels (IC₅₀=6.8 μM) than the basal current. A2764 dihydrochloride can lead to cell depolarization and increased excitability in native cells, it has the potential for probing the role of TRESK channel in migraine and nociception .

HY-B0563AR

Ropivacaine hydrochloride monohydrate (Standard)	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease Cancer
Ropivacaine (hydrochloride monohydrate) (Standard) is the analytical standard of Ropivacaine (hydrochloride monohydrate). This product is intended for research and analytical applications. Ropivacaine hydrochloride monohydrate is a potent sodium channel blocker and blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for regional anesthesia and neuropathic pain management in vivo .

HY-B0563BS

Ropivacaine-d7 hydrochloride	Isotope-Labeled Compounds	Neurological Disease
Ropivacaine-d₇ hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) . Ropivacaine hydrochloride is a potent?sodium channel?blocker and blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain?management in vivo .

HY-103371

DCPIB Maximum Cited Publications 6 Publications Verification	Chloride Channel Potassium Channel	Neurological Disease
DCPIB is a selective, reversible and potent inhibitor of volume-regulated anion channels (VRAC). DCPIB voltage-dependently activates potassium channels *TREK1* and TRAAK, and inhibits TRESK, TASK1 and TASK3 (IC₅₀s: 0.14, 0.95, 50.72 μM, respectively). DCPIB is also a selective blocker of swelling-induced chloride current (I_Cl,swell), with an IC₅₀ of 4.1 μM. DCPIB is a useful tool for investigating structure-function studies of K2P channels .

HY-B0563C

Ropivacaine mesylate 5 Publications Verification	Sodium Channel Potassium Channel	Cardiovascular Disease Neurological Disease
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibressup>[1] . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane .

Cat. No.	Product Name	Chemical Structure

HY-B0563S1

Ropivacaine-d7
Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].

Ropivacaine-d7

Ropivacaine-d₇ is deuterium labeled Ropivacaine. Ropivacain is a potent sodium channel blocker. Ropivacain blocks impulse conduction via reversible inhibition of sodium ion influx in nerve fibrese[1][2]. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel) TREK-1 with an IC50 of 402.7 μM in COS-7 cell's membrane[3]. Ropivacaine is used for the research of neuropathic pain management[1].

HY-B0563BS

Ropivacaine-d7 hydrochloride
Ropivacaine-d₇ hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) . Ropivacaine hydrochloride is a potent?sodium channel?blocker and blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) *TREK-1* with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain?management in vivo .

Ropivacaine-d7 hydrochloride

Ropivacaine-d₇ hydrochloride is a deuterium labeled Ropivacaine (hydrochloride) (HY-B0563B) . Ropivacaine hydrochloride is a potent?sodium channel?blocker and blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibrese . Ropivacaine is also an inhibitor of K_2P (two-pore domain potassium channel) TREK-1 with an IC₅₀ of 402.7 μM in COS-7 cell's membrane . Ropivacaine is widely used for neuropathic pain?management in vivo .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.